# Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis

> **NCT07442045** · — · RECRUITING · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 150 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT07442045
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-06-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07442045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07442045, "Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT07442045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*